26289409|t|Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.
26289409|a|Alzheimer's disease (AD) is a polygenic and multifactorial disease with a complex inheritance caused by the formation of amyloid plaques and neurofibrillary tangles in the brain. Increasing evidence indicates that many genes including interleukin-6 (IL-6) and alpha 2-macroglobulin (A2M) may contribute to the pathogenesis of AD. The A2M gene encodes alpha2-macroglobulin which specifically binds with the beta-amyloid peptides and prevents fibril formation. Protein of the IL-6 gene linked to beta-amyloid (betaA) aggregation was detected in betaA plaques in the brain of AD patients. The aim of the present study is to investigate the relationship of the IL-6 and A2M gene polymorphisms with AD and also the impact of rivastigmine on AD patients regarding their genotypes on IL-6 and A2M genes in 150 Iranian AD patients under rivastigmine therapy and 150 matched healthy controls. The results indicated that IL-6 G and C alleles had significant positive and negative association with AD, respectively, (P = 0.0001, relative risks (RR) = 1.39) and frequency of AD patients carrying IL-6 GG genotype was significantly in higher proportion in familial Alzheimer's disease (FAD) patients compared to controls (P = 0.02, RR = 2.25), and the IL-6 CC genotype was significantly protective against AD (P = 0.0003, RR = 0.65). Genotype analysis of A2M gene showed a significant positive correlation between A2M AA genotype and the AD patients (sporadic Alzheimer's disease (SAD) and FAD) (P = 0.001, RR = 1.56), proposing it as a possible risk factor for AD. Drug response from pharmacogenetic viewpoint after 3-year follow-up of AD patients and Clinical Dementia Rating (CDR) analysis demonstrated that AD patients carrying bigenic genotype IL-6 CC-A2M AG (DeltaCDR = 4.5) and male patients with IL-6 CC genotype (DeltaCDR = 3.83) provided the best response and the A2M GG genotype (DeltaCDR = 7.97) and bigenic genotype IL-6 GG-A2M GG (DeltaCDR = 8.5) conferred the worst response to the rivastigmine, suggesting likely involvement of genotype-specific response to rivastigmine therapy in AD patients. The results also propose that in view of the fact that C and G alleles created by nucleotide changes in the promoter region of IL-6 gene and this may affect the expression of the IL-6 gene and, hence, susceptible and protective role of GG and CC genotype in AD might be caused by higher and lower expression of IL-6 cytokine, respectively.
26289409	39	51	Rivastigmine	Chemical	MESH:D000068836
26289409	83	86	A2M	Gene	2
26289409	91	95	IL-6	Gene	3569
26289409	113	124	Alzheimer's	Disease	MESH:D000544
26289409	125	133	Patients	Species	9606
26289409	135	154	Alzheimer's disease	Disease	MESH:D000544
26289409	156	158	AD	Disease	MESH:D000544
26289409	256	271	amyloid plaques	Disease	MESH:D058225
26289409	276	299	neurofibrillary tangles	Disease	MESH:D055956
26289409	370	383	interleukin-6	Gene	3569
26289409	385	389	IL-6	Gene	3569
26289409	395	416	alpha 2-macroglobulin	Gene	2
26289409	418	421	A2M	Gene	2
26289409	461	463	AD	Disease	MESH:D000544
26289409	469	472	A2M	Gene	2
26289409	486	506	alpha2-macroglobulin	Gene	2
26289409	609	613	IL-6	Gene	3569
26289409	708	710	AD	Disease	MESH:D000544
26289409	711	719	patients	Species	9606
26289409	792	796	IL-6	Gene	3569
26289409	801	804	A2M	Gene	2
26289409	829	831	AD	Disease	MESH:D000544
26289409	855	867	rivastigmine	Chemical	MESH:D000068836
26289409	871	873	AD	Disease	MESH:D000544
26289409	874	882	patients	Species	9606
26289409	912	916	IL-6	Gene	3569
26289409	921	924	A2M	Gene	2
26289409	946	948	AD	Disease	MESH:D000544
26289409	949	957	patients	Species	9606
26289409	964	976	rivastigmine	Chemical	MESH:D000068836
26289409	1046	1050	IL-6	Gene	3569
26289409	1122	1124	AD	Disease	MESH:D000544
26289409	1198	1200	AD	Disease	MESH:D000544
26289409	1201	1209	patients	Species	9606
26289409	1219	1223	IL-6	Gene	3569
26289409	1287	1306	Alzheimer's disease	Disease	MESH:D000544
26289409	1308	1311	FAD	Disease	MESH:D000544
26289409	1313	1321	patients	Species	9606
26289409	1374	1378	IL-6	Gene	3569
26289409	1428	1430	AD	Disease	MESH:D000544
26289409	1477	1480	A2M	Gene	2
26289409	1536	1539	A2M	Gene	2
26289409	1560	1562	AD	Disease	MESH:D000544
26289409	1563	1571	patients	Species	9606
26289409	1573	1601	sporadic Alzheimer's disease	Disease	MESH:D000544
26289409	1603	1606	SAD	Disease	MESH:D003865
26289409	1612	1615	FAD	Disease	MESH:D000544
26289409	1684	1686	AD	Disease	MESH:D000544
26289409	1759	1761	AD	Disease	MESH:D000544
26289409	1762	1770	patients	Species	9606
26289409	1784	1792	Dementia	Disease	MESH:D003704
26289409	1833	1835	AD	Disease	MESH:D000544
26289409	1836	1844	patients	Species	9606
26289409	1871	1875	IL-6	Gene	3569
26289409	1879	1882	A2M	Gene	2
26289409	1912	1920	patients	Species	9606
26289409	1926	1930	IL-6	Gene	3569
26289409	1996	1999	A2M	Gene	2
26289409	2051	2055	IL-6	Gene	3569
26289409	2059	2062	A2M	Gene	2
26289409	2119	2131	rivastigmine	Chemical	MESH:D000068836
26289409	2196	2208	rivastigmine	Chemical	MESH:D000068836
26289409	2220	2222	AD	Disease	MESH:D000544
26289409	2223	2231	patients	Species	9606
26289409	2360	2364	IL-6	Gene	3569
26289409	2412	2416	IL-6	Gene	3569
26289409	2491	2493	AD	Disease	MESH:D000544
26289409	2544	2548	IL-6	Gene	3569
26289409	Positive_Correlation	MESH:D003865	2
26289409	Negative_Correlation	MESH:D000068836	MESH:D000544
26289409	Association	MESH:D000544	2
26289409	Association	MESH:D000544	3569

